List of Mirvaso drug patents

Mirvaso is owned by Galderma Labs Lp.

Mirvaso contains Brimonidine Tartrate.

Mirvaso has a total of 12 drug patents out of which 0 drug patents have expired.

Mirvaso was authorised for market use on 23 August, 2013.

Mirvaso is available in gel;topical dosage forms.

Mirvaso can be used as topical treatment of facial erythema of rosacea.

The generics of Mirvaso are possible to be released after 13 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(1 year, 3 months from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2025

(2 years from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema
May, 2025

(2 years from now)

US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis
May, 2025

(2 years from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea
Aug, 2025

(2 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(8 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use
Jun, 2031

(8 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use
Jun, 2031

(8 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition
Jun, 2031

(8 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in